How big is The Pennant Group, Inc.?

As of Jun 18, The Pennant Group, Inc. has a market capitalization of 960.73 million, with net sales of 748.17 million and a net profit of 27.80 million over the latest four quarters.

As of Jun 18, The Pennant Group, Inc. has a market capitalization of 960.73 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 748.17 million and a net profit of 27.80 million for the latest four quarters.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 293.28 million and total assets of 766.36 million.

What does The Pennant Group, Inc. do?

The Pennant Group, Inc. is a holding company that provides healthcare services to seniors in the U.S., with recent net sales of $210 million and a market cap of approximately $960.73 million. Key financial metrics include a P/E ratio of 35.00 and a return on equity of 9.54%.

Overview: <BR>The Pennant Group, Inc. is a holding company that provides healthcare services to the senior population in the United States, operating in the Pharmaceuticals & Biotechnology industry within the micro-cap market.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 210 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 9 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 960.73 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 35.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.22 <BR>Return on Equity: 9.54% <BR>Price to Book: 3.16<BR><BR>Contact Details: <BR>Address: 1675 E Riverside Dr Ste 150, EAGLE ID: 83616-7471 <BR>Tel: 1 208 9576025 <BR>Website: https://www.pennantgroup.com/

Should I buy, sell or hold The Pennant Group, Inc.?

Who are in the management team of The Pennant Group, Inc.?

As of March 2022, The Pennant Group, Inc.'s management team includes Mr. Daniel Walker as Chairman and CEO, with Mr. Christopher Christensen as a Director and several Independent Directors: Mr. Stephen Covey, Mr. Scott Lamb, Mr. Roderic Lewis, and Dr. John Nackel.

As of March 2022, the management team of The Pennant Group, Inc. includes Mr. Daniel Walker, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, the Board of Directors comprises Mr. Christopher Christensen as a Director, along with several Independent Directors: Mr. Stephen Covey, Mr. Scott Lamb, Mr. Roderic Lewis, and Dr. John Nackel.

Is The Pennant Group, Inc. technically bullish or bearish?

As of September 19, 2025, The Pennant Group, Inc. is in a bearish trend, indicated by mixed MACD signals and underperformance against the S&P 500, with a 1-year return of -31.11% compared to the S&P 500's 16.64%.

As of 19 September 2025, the technical trend for The Pennant Group, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength indicated by the weekly MACD being mildly bullish while the monthly MACD is mildly bearish. The Bollinger Bands and KST both show a mildly bearish trend on both weekly and monthly time frames. Daily moving averages also reflect a mildly bearish sentiment. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a 1-year return of -31.11% compared to the S&P 500's 16.64%, and a year-to-date return of -7.32% versus the S&P 500's 13.31%.

Is The Pennant Group, Inc. overvalued or undervalued?

As of October 17, 2025, The Pennant Group, Inc. is fairly valued with a P/E ratio of 35 and a PEG ratio of 0.70, but has underperformed with a year-to-date decline of 10.86% compared to the S&P 500's 13.30% gain.

As of 17 October 2025, The Pennant Group, Inc. moved from expensive to fair in its valuation grade. The company is currently fairly valued based on its metrics. Key ratios include a P/E ratio of 35, an EV to EBITDA of 21.52, and a PEG ratio of 0.70, which suggests growth potential relative to its price. In comparison, peers such as Addus HomeCare Corp. have a P/E of 22.05, while Hims & Hers Health, Inc. is considered expensive with a P/E of 54.76.<BR><BR>Despite its fair valuation, The Pennant Group, Inc. has underperformed in recent returns, with a year-to-date decline of 10.86% compared to a 13.30% gain in the S&P 500, and a one-year drop of 32.78% against a 14.08% increase in the index. This performance indicates potential challenges ahead, even as the valuation appears reasonable relative to its peers.